Sunday, August 09, 2020 8:36:18 PM
All kinds of ways. Some bad, some good.
And? The only good way is to bring cash to the bottom line.
Those earnings will cause some of the beauty contest judges to vote for us. The judges are the shareholders that buy our stock. Our PE Ratio goes way over industry norms. 100 PE will put our shares and total Market Cap out of even the biggest Pharma Co. grasp.
Those that say my 100 PE Ratio is not possible, I do not care. It can and it will be 100 PE or higher.
Why? Because we have a beautiful drug. Can you imagine the press as we go through cancer FDA Trials. Covid was scary but Cancer is a different deal.
What was Amazon's PE 4 years ago when the stock was around 600$. One of my brightest old time broker pals was all over Amazon.
Use some of the cash to do self tenders for large numbers of shares.
Bad ways? Risky deals to actually make CYDY less attractive. Merge with another company where CYDY Board of Directors and management assumes control.
Doing something like that will cause a shareholder revolt and the management will be replaced.
I strongly suggest to management that they bring the revs to the bottom line. Buy back shares. In a few years we, CYDY can be buying small cap promising Bio companies.
CYDY might even buy a huge Put position in Gilead. Help Adam out.
And? The only good way is to bring cash to the bottom line.
Those earnings will cause some of the beauty contest judges to vote for us. The judges are the shareholders that buy our stock. Our PE Ratio goes way over industry norms. 100 PE will put our shares and total Market Cap out of even the biggest Pharma Co. grasp.
Those that say my 100 PE Ratio is not possible, I do not care. It can and it will be 100 PE or higher.
Why? Because we have a beautiful drug. Can you imagine the press as we go through cancer FDA Trials. Covid was scary but Cancer is a different deal.
What was Amazon's PE 4 years ago when the stock was around 600$. One of my brightest old time broker pals was all over Amazon.
Use some of the cash to do self tenders for large numbers of shares.
Bad ways? Risky deals to actually make CYDY less attractive. Merge with another company where CYDY Board of Directors and management assumes control.
Doing something like that will cause a shareholder revolt and the management will be replaced.
I strongly suggest to management that they bring the revs to the bottom line. Buy back shares. In a few years we, CYDY can be buying small cap promising Bio companies.
CYDY might even buy a huge Put position in Gilead. Help Adam out.
Recent CYDY News
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
